Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling-Reference-Cited by-同舟云学术

Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling

Published:2015-11-06 Issue:5 Volume:7 Page:5521-5537
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mediani Laura¹,Gibellini Federica¹,Bertacchini Jessika¹²,Frasson Chiara³,Bosco Raffaella¹,Accordi Benedetta³,Basso Giuseppe³,Bonora Massimo⁴,Calabrò Maria Luisa⁵,Mattiolo Adriana⁵,Sgarbi Gianluca⁶,Baracca Alessandra⁶,Pinton Paolo⁴,Riva Giovanni⁷,Rampazzo Enrico⁸,Petrizza Luca⁸,Prodi Luca⁸,Milani Daniela²,Luppi Mario⁷,Potenza Leonardo⁷,De Pol Anto¹,Cocco Lucio⁶,Capitani Silvano²,Marmiroli Sandra¹

Affiliation:

1. Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, Modena, Italy

2. Department of Morphology, Surgery and Experimental Medicine, Section of Anatomy and Histology and LTTA Center, University of Ferrara, Ferrara, Italy

3. Department of Woman's and Child's Health and Institute of Pediatric Research - Città della Speranza Foundation, University of Padova, Padova, Italy

4. Department of Morphology, Surgery and Experimental Medicine Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy

5. Immunology and Molecular Oncology, Veneto Institute of Oncology, IOV IRCCS, Padova, Italy

6. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy

7. Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy

8. Department of Chemistry, University of Bologna, Bologna, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Deficiencies Underlie Plasmacytoid Dendritic Cell Exhaustion After Viral Infection;2024-03-03

2. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells;Advances in Biological Regulation;2023-08

3. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma;International Journal of Molecular Sciences;2023-03-13

4. Eukaryotic Translation Initiation Factor 3 Subunit D is One Clinical Target and Pre-Tumor Gene for Non Hodgkin Lymphoma to Promote Cell Proliferation Through Warburg Effect by Interacting with GRP78;Journal of Biomaterials and Tissue Engineering;2023-03-01

5. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma;Drug Resistance Updates;2022-03